Genetic testing in cardiovascular diseases

Current Opinion in Cardiology

Volumn 25, Issue 3, 2010, Pages 243-248

  Hofman, Nynke ^a   Langen, Irene Van ^a   Wilde, Arthur A M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cardiogenetics; Genetic counseling; Genetic testing

Indexed keywords

CARDIOVASCULAR DISEASE; FOLLOW UP; GENE IDENTIFICATION; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEART DISEASE; HUMAN; LONG QT SYNDROME; MUTATIONAL ANALYSIS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PUBLICATION; REVIEW;

ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; GENETIC COUNSELING; GENETIC TESTING; HUMANS; MUTATION; NETHERLANDS;

EID: 77951964887     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283374d69     Document Type: Review

References (45)

1. van Langen IM, Hofman N, Tan HL, Wilde AA. Family and population strategies for screening and counseling of inherited cardiac arrhythmias. Ann Med 2004;36:116-124.
2. Christiaans I, Birnie E, Bonsel GJ, et al. Uptake of genetic counseling and predictive DNA testing in hypertrophic cardiomyopathy. Eur J Hum Genet 2008;16:1201-1207.
3. van der Roest WP, Pennings JM, Bakker M, et al. Family letters are an effective way to inform relatives about inherited cardiac disease. Am J Med Genet Part A 2009; 149A: 357-363.
4. Cotton RG, Scriver CR. Proof of disease causing mutation. Hum Mut 1998;12:1-3.
5. Den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000;15:7-12;
6. Erratum in: Hum Mutat 2002;20:403.
7. Murphy RT, Starling RC. Genetics and cardiomyopathy: where are we now? Cleve Clin J Med 2005;72:465-466; 469-470, 472-473 passim.
8. Christiaans I, van Langen IM, Birnie E, et al. Quality of life and psychological distress in hypertrophic cardiomyopathy mutations carriers: a cross-sectional cohort study. Am J Med Genet Part A 2009; 149A: 602-612.
9. Christaans I, van Langen IM, Birnie E, et al. Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients' perspective. Am J Med Genet Part A 2009; 149A: 1444-1451. Evaluation of 123 predictively molecular tested Dutch HCM carriers shows that they value the counseling process positively. Point of concern is the risk management and the organization of the regular cardiologic follow-up of the carriers.
10. European Society of Human Genetics. Genetic testing in asymptomatic minors. Recommendations of the European Society of Human Genetics. Eur J Hum Genet 2009;17:720-721.
11. Meulenkamp TM, Tibben A, Mollema ED, et al. Predictive genetic testing for cardiovascular diseases: impact on carrier children. Am J Med Genet A 2008; 146A: 3136-3146.
12. Smets EMA, Stam MMH, Meulenkamp TM, et al. Health-related quality of life of children with a positive carrier status for inherited cardiovascular diseases. Am J Med Genet Part A 2008; 146A: 700-707.
13. Kapplinger JD, Tester DJ, Salisbury BA, et al. Spectrum and prevalence of mutations from the first 2, 500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm 2009;6:1297-1303. Largest study of consecutive genetic testing of patients with a less or more probable LQTS providing a large compendium of probably causal variants.
14. Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach togenotyping in clinical practice. JAMA 2005;294:2975-2980.
15. Taggart NW, Haglund CM, Tester DJ, Ackerman MJ. Diagnostic miscues in congenital long-QT syndrome. Circulation 2007;115:2613-2620.
16. Kapa S, Tester DJ, Salisbury BA, et al. Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation 2009;120:1752-1760. First attempt to determine the relevance of the detected missense mutations in the LQTS.
17. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102:1178-1185.
18. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Effect of clinical phenotypeon yield of long QT syndrome genetic testing. J Am Coll Cardiol 2006;47:764-768.
19. Schulze-Bahr E, Eckardt L, Breithardt G, et al. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome. Different incidences in familial and sporadic disease. Hum Mutat 2003;21:651-652.
20. Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol 2009;2:6-15. An overview of the cost-effectiveness of genetic testing. It is concluded that genetic testing can be performed at reasonable cost in individuals with conclusive clinical diagnosis of LQTS and CPVT, or a type 1 ECG with delayed conduction in BrS.
21. Smits JP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol 2002;40:350-356.
22. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. Comprehensive open reading frame mutational analysis of the RYR2-encoded ryanodine receptor/calcium channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exerciseinduced long QT syndrome. J Am Coll Cardiol 2009;54:2065-2074. This study presents the increasing yield of finding mutations in CPVT patients, by expanding the number of exons to screen in the RYR2 gene.
23. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106:69-74.
24. Postma AV, Denjoy I, Kamblock J, et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 2005;42:863-870.
25. Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 2006;81:459-467.
26. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008;83:630-638.
27. Erdmann J, Daehmlow S, Wischke S, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Clin Genet 2003;64:339-349.
28. Richard P, Charron P, Carrier L, et al. EUROGENE Heart Failure Project. Circulation 2003;107:2227-2232.
29. Andersen PS, Havndrup O, Hougs L, et al. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. Hum Mutat 2009;30:363-370.
30. Van Tintelen JP, Entius MM, Bhuiyan ZA, et al. Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 2006;113:1650-1658.
31. Barahona-Dussault C, Benito B, Campuzano O, et al. Role of genetic testing in arrhythmogenic right ventricular cardiomyopathy/dysplasia: experience from a single center prospective cohort. Clin Genet 2010;77:37-48.
32. Marcus FI, Zareba W, Calkins H, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary study. Heart Rhythm 2009;6:984-992.
33. Møller DV, Andersen PS, Hedley P, et al. The role of sarcomere gene mutations in patients with idiopathic dilated cardiomyopathy. Eur J Hum Genet 2009;17:1241-1249.
34. van Tintelen JP, Hofstra RM, Katerberg H, et al. High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. Am Heart J 2007;154:1130-1139.
35. Hershberger RE, Parks SB, Kushner JD, et al. Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin Transl Sci 2008;1:21-26.
36. Alders M, Jongbloed R, Deelen W, et al. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly onefourth of the HCM cases in the Netherlands. Eur Heart J 2003;24:1848-1853.
37. Graham RM, Ownes WA. Pathogenesis of inherited forms of dilated cardiomyopathy. N Engl J Med 1999;341:1759-1762.
38. Keeling PJ, McKenna WJ. Clinical genetics of dilated cardiomyopathy. Herz 1994;19:91-96.
39. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task force of the working group of myocardial and pericardial disease of the European Society of Cardiology and of the scientific council on cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994;71:215-218.
40. Basso C, Corrado D, Marcus FI, et al. Arrhythmogenenic right ventricular cardiomyopathy. Lancet 2009;373:1289-1300.
41. Nava A, Thiene G, Canciani B, et al. Familial occurrence of right ventricular dysplasia: a study involving nine families. J Am Coll Cardiol 1989;12:1222-1228.
42. Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2007;50:1813-1821.
43. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the long-QT syndrome. Circulation 2009;120:1761-1767.
44. Hofman N, Wilde AA, Kääb S, et al. Diagnostic criteria for congenital long QT syndrome in the era of molecular genetics. Do we need a scoring system? Eur Heart J 2007;28:575-580. (Pubitemid 47355496)
45. Hofman N, Tan HL, Alders M, et al. Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment? JACC 2010 (in press).